IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA Biosciences has entered a clinical collaboration with Roche to evaluate its PRMT5 inhibitor IDE892 in combination with Roche's pan-RAS inhibitor RG6505. The study will target patients with pancreatic ductal adenocarcinoma (PDAC) that carry an MTAP deletion, a biomarker present in up to 40% of PDAC cases.
Key figures
- Drug Name
- IDE892
- Phase Of Trial
- Phase 1
- Mtap deletion prevalence pdac
- up to 40%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.